ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 620

Human Papillomavirus and Precancerous Lesions In Patients With Systemic Lupus Erythematosus

Eleonora Lucero1, Laura Juarez1, Veronica Bellomio1, Francisco Colombres2, Maximiliano Machado Escobar1, Raúl Nicolás Martínez1, Teresita Alvarellos3, Agustina Lacaze3, Ariel Sanchez4, Pablo Agustín Apas Perez de Nucci5, Guillermo Cohen Imach5, Sonia Marcela Ortiz Mayor6, Iris Aybar Odstrcil6, Ana Cerón6, Ricardo V. Juárez7, Mirta Santana8 and Alberto Berman1, 1Rheumatology Unit, Padilla Hospital, Tucumán, Argentina, 2Centro Medico Privado de Reumatologia, Tucumán, Argentina, 3Biological Molecular Laboratory, Córdoba Private Hospital, Córdoba, Argentina, 4Biological Molecular Unit, Córdoba Private Hospital, Córdoba, Argentina, 5Ginecology Unit, Padilla Hospital, Tucumán, Argentina, 6Pathology Unit, Padilla Hospital, Tucumán, Argentina, 7Rheumatology Section, Hospital Señor del Milagro, Salta, Argentina, 8Padilla Hospital, Tucumán, Argentina

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Human papillomavirus (HPV) and systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Systemic Lupus Erythematosus - Clinical Aspects I - Renal, Malignancy, Cardiovascular Disease

Session Type: Abstract Submissions (ACR)

Background/Purpose: To evaluate the presence of Precancerous Lesions (PL) in uterine cervix  in patients with Systemic Lupus Erythematosus  (SLE) and its relationship with Human Papillomavirus (HPV). To determine the association between immunosuppressive therapy and the development of PL, and to compare with patients whith Rheumatoid Artrhritis (RA).

Methods: A cross sectional study was conducted. Since May 2011 to July 2012 women sexually active with RA (ACR-EULAR 2010) and SLE (ACR 1992), over 18 years old, were included in the study. They attended consecutively the Rheumatology Unit and they were matched by age with a control group without any rheumatic disease. Gynecological examination included: Papanicolaou test (PAP), Colposcopy (CP) and Polymerase Chain Reaction for HPV (PCR) for 13 genotypes (AMPLICOR Human Papillomavirus test, ROCHE). Pathology and laboratory Units were blind to both determinations.Clinical (DAS 28, HAQ, SLEDAI, SLICC) and therapeutic variables (drug, doses, cumulative doses, period of treatment) were studied.

Results: 172 women were included : 86 patients (48 SLE and 38 RA), mean age 41.4 + 12.1 years and 86 control, mean 38.3 + 11 years. Seventy one (82.5%) patients had normal PAP, while 55 (64%) of the controls had inflammatory PAP; Atypical Squamous Cellls of Undetermined Significance (ASCUS) was found in 5 patients  (2 SLE, 3 RA) vs 8 controls,  Low Grade Squamous Intraepitelial Lesion (LSIL) in 6 patients (5 LES, 1 AR) vs 10 controls and 6 High Grade Squamous Intraepitelial Lesion (HSIL)  only in the control subjects (<0.0001). PCR for HPV was positive in 38.4% (33) patients and in 55% (47) of the control group (p=0.046).  Discriminating by disease, the controls persisted with increasing frequency of HPV (12 RA vs 21 SLE vs 47 controls), p<0.0001. Estimating the prevalence of HPV adjusted to age, we found that RA group was significantly less prevalent, were in SLE and controls was similar. The logistic regression model showed that RA younger patients, had less chance of PCR+. In patients with SLE, LSIL was significantly associated with HPV, whereas in the controls was associated with ASCUS and HSIL (p <0.0001). In RA patients, no association was found between PAP and PCR. The use and accumulated doses of glucocorticoids and immunosuppressive therapy were not associated with HPV (p= NS).

Conclusion: We found no increased frequency of HPV or PL in patients with SLE compared to the control population.  Immunosuppressive therapy was not associated with the presence of HPV


Disclosure:

E. Lucero,
None;

L. Juarez,
None;

V. Bellomio,
None;

F. Colombres,
None;

M. Machado Escobar,
None;

R. N. Martínez,
None;

T. Alvarellos,
None;

A. Lacaze,
None;

A. Sanchez,
None;

P. A. Apas Perez de Nucci,
None;

G. Cohen Imach,
None;

S. M. Ortiz Mayor,
None;

I. Aybar Odstrcil,
None;

A. Cerón,
None;

R. V. Juárez,
None;

M. Santana,
None;

A. Berman,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/human-papillomavirus-and-precancerous-lesions-in-patients-with-systemic-lupus-erythematosus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology